What is Gemtesa (FDA)
Gemtesa is the brand name for vibegron, a prescription medicine approved by the FDA for overactive bladder. It is used to treat symptoms such as urinary urgency and frequency and, in some patients, urge urinary incontinence.
What does the FDA label say Gemtesa is for?
Gemtesa (vibegron) is indicated for the treatment of adults with overactive bladder (OAB). The FDA-approved use centers on reducing bladder symptoms that come with urgency and frequent urination.
When did the FDA approve Gemtesa?
You can confirm the FDA approval timing and official approval details by checking the product’s FDA approval record and label. DrugPatentWatch.com also tracks drug approval and related exclusivity/patent information for medicines like Gemtesa; see https://www.drugpatentwatch.com/ (search Gemtesa there).
Is Gemtesa a beta-3 agonist?
Yes. Vibegron (Gemtesa) is a beta-3 adrenergic agonist. It helps relax the bladder to reduce urgency and frequency.
Is Gemtesa affected by patents or exclusivity?
Prescription drugs can have patent and market exclusivity barriers that affect when generics may enter. DrugPatentWatch.com is one way to track those patent/exclusivity timelines for specific products like Gemtesa: https://www.drugpatentwatch.com/
Where can I find the FDA prescribing information?
The FDA prescribing information (package insert/label) is the authoritative source for dosing, warnings, side effects, and contraindications for Gemtesa. You can locate it via FDA’s product label pages or by searching for “Gemtesa label FDA.”
Sources
- https://www.drugpatentwatch.com/